Nonprofits›Memorial Sloan-Kettering Cancer Center
Medical Research
Memorial Sloan-Kettering Cancer Center
NEW YORK, NY
Total revenue
—
Total expenses
—
Net assets
—
Grants received
$46.5M
163 grants
EIN
131624182
Tax year
—
Grants received
Showing 163 of 163
FromAmountPurposeYear
$1.4M
YOUNG INVESTIGATOR AWARD, LONG-TERM INTERNATIONAL FELLOWSHIP
2024
$56K
SUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER.
2024
$199K
SUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER.
2023
$161K
SUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER.
2022
$56K
SUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER.
2021
$157K
SUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER.
2020
$205K
SUPPORTED BASIC AND CLINICAL RESEARCH IN CANCER PERFORMED AT MSKCC AND RESULTING IN MORE THAN 15 PEER REVIEWED SCIENTIFIC PUBLICATIONS.
2019
$216K
MEMORIAL SLOAN-KETTERING CANCER CENTER ("MSKCC") ($215,795) -A) SUPPORT THE RESEARCH AND CLINICAL STUDIES FOR RETINOBLASTOMA ($150,000): THESE FUNDS SUPPORTED THE RESEARCH CONDUCTED AT MSK DURING THE YEAR. IT RESULTED IN 16 PUBLICATIONS IN PEER REVIEWED JOURNALS INCLUDING THE BRITISH JOURNAL OF OPHTHALMOLOGY, OPHTHALMOLOGY, AMERICAN JOURNAL OF OPHTHALMOLOGY, NEOPLASIA, PLOS1, INT J OF RETINA AND VITREOUS, JAMA OPHTHALMOLOGY, OPHTHALMIC GENETICS AND IOVS. THE TOTAL NUMBER OF AUTHORS SUPPORTED BY THESE FUNDS IN 2018 WAS 52.B) CYCLE FOR SURVIVAL ($55,000): DONATION TO THE CYCLE CHARITY-THE YEARLY FUND RAISER AT MSK TO SUPPORT RESEARCH IN RARE CANCERS.C) RESEARCH EQUIPMENT AND SUPPLIES ($10,795): COMPUTERS, STATISTICIANS, REPRINTS, PRODUCTION OF SCIENTIFIC ARTICLES AND ONGOING RESEARCH AT MSK, INCLUDING CHARGES BY LABS FOR PROCESSING SPECIMENS FOR RESEARCH.
2018
$8K
To provide leadership in the prevention, treatment and cure of cancer through excellence, vision and cost effectiveness in patient care, outreach programs, research, and education.
2018
Funded by
$46.5M from 52 funders · 163 grants · 2016–2024
Cancer Research Institute Inc
$8.5M · 6 grants · 2018–2023
National Philanthropic Trust
$5.9M · 4 grants · 2017–2023
Fred Hutchinson Cancer Research Center
$5.2M · 19 grants · 2017–2021
American Cancer Society Inc
$5.0M · 3 grants · 2022–2024
Conquer Cancer Foundation Of The
$4.2M · 3 grants · 2020–2024
Fred Hutchinson Cancer Center
$2.3M · 7 grants · 2021–2023
Swim Across America Inc
$1.7M · 4 grants · 2020–2024
Ira Sohn Conference Foundation
$1.5M · 4 grants · 2020–2023
Details
EIN131624182
NTEE codeH30Z
Subsection03
Ruling date1962-01